Memos and Guidance for DCP Clinical Trials Investigators during the COVID-19 Pandemic

Date Posted

COVID-19 is an emerging, rapidly evolving situation. In addition to the information sources listed in the web header, the National Cancer Institute and the Division of Cancer Prevention have issued guidance for DCP investigators during the COVID-19 pandemic. Those materials are consolidated here for convenience:

Image of COVID-19 virus.

NCI Central Institutional Review Board (CIRB) Guidance for the New Coronavirus:

FDA Guidance on Conduct of Clinical Trials of Medical Products during COVID-19 Pandemic Guidance for Industry, Investigators, and Institutional Review Boards


Last updated: May 8, 2020